This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Scientific Advisory Board
Arecor is honoured to have the support of a world class Global Diabetes Scientific Advisory Board to support the scientific, pre-clinical and clinical development of its novel proprietary insulin formulations. The SAB brings together three world-renowned scientists and endocrinologists from the US and EU with extensive expertise in the field of diabetes and related conditions.
-
Bruce Buckingham, MD
Dr. Bruce Buckingham has served as a member of our Scientific Advisory Board since September 2017. He is Professor of Paediatrics (Endocrinology) at the Lucile Salter Packard Children’s Hospital, Stanford University School of Medicine. Dr. Buckingham’s major interest is in type 1 diabetes mellitus, continuous glucose sensor, and the development of an artificial pancreas.
READ MORE ↓READ LESS ↑His other research interests include using continuous glucose monitoring and algorithms to control blood glucose levels in intensive care units. He is currently working on the clinical trial: Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes.
-
Eda Cengiz, MD MHS FAAP
Dr. Eda Cengiz has served as a member of our Scientific Advisory Board since September 2017. She is Professor of Pediatrics at the University of California, San Francisco and Director of the Cross-bay Pediatric Diabetes Program. For over 14 years, Dr Cengiz was a faculty member with Yale Diabetes Research Group and has conducted diabetes related clinical studies focusing on methods to accelerate insulin action, diabetes technology, and closed-loop systems. She was Director of Yale’s Insulin Pharmacokinetics and Pharmacodynamics (PK-PD) Research Study Center and one of the founding Investigators of the pediatric diabetes registry and type 1 diabetes exchange registry.
READ MORE ↓READ LESS ↑Dr. Cengiz’s prospectively designed clinical study (Early Cardiovascular Disease Markers for Children with Type 1 Diabetes (Jerusalem, Israel) (2009-2012), investigates signs of early cardiovascular disease in children with type 1 diabetes in the US and in Israel.
-
Thomas R. Pieber, MD
Dr. Thomas Pieber has served as a member of our Scientific Advisory Board since September 2017. He is a clinical specialist in endocrinology and diabetes mellitus, whose research is dedicated to the relationship of inflammation, energy homeostasis and human diseases. His group has developed a novel technique called open-flow microperfusion (OFM) which is used to explore energy metabolism in adipose and muscle tissue in diabetes.
READ MORE ↓READ LESS ↑Recently Dr. Pieber’s research has also addressed the role of 15-hydroxy-vitamin D in immune tolerance and autoimmunity. In a joint research effort with leading obesity centres in Europe, his group currently addresses the role of immune competent cells and novel pathways of chronic inflammation in obesity and diabetes. Dr. Pieber is Chairman of the Division of Endocrinology and Metabolism at the Medical University of Graz.